title: Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma.
abstract: OBJECTIVE
  Retrospective database study comparing upper and lower airway-related outcomes for patients with rhinitis and co-morbid asthma receiving mometasone furoate--an intranasal corticosteroid with low systemic bioavailability--or an oral antihistamine.
  
  
  METHODS
  395 patients prescribed intranasal mometasone were matched on 10 demographic and respiratory-related criteria in a 1:2 ratio to 790 patients prescribed oral antihistamine. Asthma and rhinitis control were assessed over one year using predefined composite proxy measures.
  
  
  RESULTS
  Asthma control was achieved by 309/395 (78.2%) versus 580/790 (73.4%; p=0.071) patients in the mometasone and antihistamine cohorts, respectively. Rhinitis control was achieved by 293 (74.2%) versus 539 (68.2%; p=0.035), respectively. The adjusted odds ratios for antihistamines, relative to mometasone, were 0.71 (95% CI, 0.52-0.98) for achieving asthma control and 0.74 (95% CI, 0.56-0.97) for achieving rhinitis control.
  
  
  CONCLUSIONS
  Patients with rhinitis and co-morbid asthma initiating rhinitis therapy achieved significantly better upper as well as lower airway outcomes with intranasal mometasone than with oral antihistamine.
authors.affiliation: Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK. david@respiratoryresearch.org
authors.forename: David
authors.initials: D
authors.lastname: Price
authors.forename: Linda
authors.initials: L
authors.lastname: Kemp
authors.forename: Erika
authors.initials: E
authors.lastname: Sims
authors.forename: Julie
authors.initials: J
authors.lastname: von Ziegenweidt
authors.forename: Prakash
authors.initials: P
authors.lastname: Navaratnam
authors.forename: Amanda J
authors.initials: AJ
authors.lastname: Lee
authors.forename: Alison
authors.initials: A
authors.lastname: Chisholm
authors.forename: Elizabeth V
authors.initials: EV
authors.lastname: Hillyer
authors.forename: Gokul
authors.initials: G
authors.lastname: Gopalan
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D016001:Confidence Intervals; D005260:Female; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D016017:Odds Ratio; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D006633:Histamine Antagonists; D011244:Pregnadienediols; D000068656:Mometasone Furoate